ERA4TB

As we come to the end of 2024, ERA4TB would like to take this opportunity to wish all our partners, collaborators and followers a very Happy Christmas and holiday season. We have achieved a lot over the last year including:   ⭐ Completion of patient recruitment in July 2024, ahead of the expected completion date, to the first Phase 1 trial in ERA4TB’s validated academic Clinical Trial Unit network. ⭐ Four new publications have been accepted and published during 2024 within the ERA4TB Consortium. Read them now: https://lnkd.in/dqBnBqjX ⭐ In May 2024, ERA4TB celebrated the first joint symposium with UNITE4TB. Hosted by Uppsala University, the symposium brought together around 200 people to discuss the key opportunities and challenges facing TB drug development today, and to hear about the exciting progress being made in both projects. ⭐ On 27 September 2024, ERA4TB researchers from Universidad de Zaragoza and Università di Pavia took part in local events hosted as part of the European Researchers' Night, the largest science outreach project in Europe. ⭐ On 12 November 2024, ERA4TB hosted the “TB Drug Regimens Development School: Advanced Preclinical and Translational tools within the Public-Private ERA4TB consortium hub” workshop at the International Union Against Tuberculosis and Lung Disease (The Union) World Conference on Lung Health in Bali, Indonesia. ⭐ On 28 November 2024, our colleagues from Universidad de Zaragoza collected the Spanish edition of the Quality Innovation Award. The award was within the category of innovation with potential and was presented for their work on the Hollow Fibre System implementation within ERA4TB.   We look forward to continuing our mission of developing new treatment regimens for Tuberculosis in 2025! #Tuberculosis #TB #TBresearch #AMR #Earlyphaseresearch Innovative Health Initiative (IHI), AMR Accelerator, Universidad Carlos III de Madrid, Institut Pasteur, GSK, ARAID administracion, Araid administracion, Institut Pasteur de Lille, SYNAPSE Research Management Partners, Forschungszentrum Borstel, Leibniz Lungenzentrum, innovative Medicines for Tuberculosis (iM4TB) Critical Path Institute (C-Path), Consiglio Nazionale delle Ricerche, Commissariat a l'Energie Atomique et aux Energies Alternatives, UK Health Security Agency, EPFL, University of Cologne, Università degli Studi di Padova, NICE - National Institute for Health and Care Excellence, Sciensano, BIOASTER, QPS Netherlands B.V., grit42, Evotec, The Janssen Pharmaceutical Companies of Johnson & Johnson, Bill & Melinda Gates Foundation, TB Alliance, University of Dundee, Aliri Bioanalysis, Fundación para la Investigación Biomédica HULP, Latvian Institute of Organic Synthesis, Centre Investigació Medicament (CIM) - Institut de Recerca Sant Pau

Our In Vitro work package (WP2) kicked off their annual meeting yesterday in Pavia, with an opening lecture from Sir Stewart Cole. Università di Pavia AMR Accelerator Innovative Health Initiative (IHI) ARAID Universidad de Zaragoza

Check out the latest news from our fellow Innovative Health Initiative (IHI) projects RespiriTB and RespiriNTM!

Last week, COMBINE consortium member grit42 announced that it would offer the grit Scientific Data Management Platform for free! Sign up to be notified upon its release in 2025: https://lnkd.in/ewejHqU9 Why is this important? Open-Sourced Platforms ensure: - Enhanced Collaboration and Data Accessibility: grit42 removes a financial barrier and opens the door for more researchers and institutions to engage in collaborative AMR research. - Sustainable Research Progress: free access to the grit platform ensures that ongoing projects can benefit from a robust data management solution without allocating additional funds to license fees beyond the projects' lifetime. - Promoting Open Science and Innovation: grit42's platform can foster an ecosystem where innovations can build upon each other, helping AMR researchers to develop and test new solutions faster. 

Sharing a couple of photos of our colleagues from at Universidad de Zaragoza as they collected the Spanish edition of the Quality Innovation Award on 28th November. The award was within the category of innovation with potential and was presented for their work on the Hollow Fibre System implementation within ERA4TB, You can watch a recording of the awards ceremony online via the YouTube channel of Centros de Excelencia: https://cutt.ly/DTLeewc #PremiosQIA Innovative Health Initiative (IHI), AMR Accelerator

We are very pleased to announce that our colleagues at Universidad de Zaragoza have been granted the Spanish edition of the Quality Innovation Award for the Hollow Fibre System implementation within ERA4TB, within the category of innovation with potential. The awards ceremony will take place tomorrow at 12:00 (CET) and can be viewed online https://lnkd.in/grXeQbY and will be available after on the YouTube channel of Centros de Excelencia: https://cutt.ly/DTLeewc  #PremiosQIA

On #EuropeanAntibioticAwarenessDay, EMA is calling medicine developers, big and small, to engage early with the Agency. We are ready to discus with you any innovative idea that may lead to development of novel antimicrobials, alternatives to antimicrobials and quick diagnostics. In the last 10 years, there has been a concerning decrease of new antibacterial and antifungal agents approved in the EU that are able to treat drug resistant infections. For example, these medicines represented less than 4% of the total EMA recommendations for a marketing authorisation. Globally, small and medium-sized enterprises (#SMEs) lead in antimicrobial research and development. However, only 3% of EMA’s registered SMEs develop and market anti-infectives. Find out more in the infosheet below. #EAAd #WAAW #AntimicrobialResistance #AMR 

Today starts World AMR Awareness Week 2024! This year is particularly unique because it follows the fourth Global High-Level Ministerial Conference on AMR held last week in Jeddah, Saudi Arabia. The AMR Accelerator – a public-private partnership involving nine European projects and 98 organisations – urges government leaders and private actors to invest in the development of antibiotics and research on antimicrobial resistance. Read more about our call to action, published in Nature Reviews Drug Discovery: https://lnkd.in/eqGbRqmg #WAAW #AntimicrobialResistance. Innovative Health Initiative (IHI)| ERA4TB | RespiriNTM | RespiriTB | European Vaccine Initiative (EVI)| UNITE4TB

Our workshop at #UnionConf2024 "TB Drug Regimens Development School: Advanced Preclinical and Translational tools within the Public-Private ERA4TB consortium hub" was well attended and it was great to see everyone being so engaged. Thank you to everyone who attended and made the event a success including our speakers from Universidad de Zaragoza, Universidad Carlos III de Madrid, Research Center Borstel, Commissariat a l'Energie Atomique et aux Energies Alternatives, Farmacología Clínica Hospital Universitario La Paz and Bill & Melinda Gates Medical Research Institute. #TBresearch #Tuberculosis #TB #earlyphasedrugdevelopment AMR Accelerator, International Union Against Tuberculosis and Lung Disease (The Union), NICE - National Institute for Health and Care Excellence, Innovative Health Initiative (IHI), EFPIA - European Federation of Pharmaceutical Industries and Associations, Bill & Melinda Gates Foundation, University of Dundee, TB Alliance

Are you attending #UnionConf2024? Come and join us tomorrow, 10:30 -1:00pm in the Bougainville Room (Bali International Convention Centre) for our workshop "TB Drug Regimens Development School: Advanced Preclinical and Translational tools within the Public-Private ERA4TB consortium hub". We are excited to introduce our guest speakers from Universidad de Zaragoza, Universidad Carlos III de Madrid, Research Center Borstel, Commissariat a l'Energie Atomique et aux Energies Alternatives, Farmacología Clínica Hospital Universitario La Paz and Bill & Melinda Gates Medical Research Institute. Register for the workshop online and come and learn more about our work. We look forward to seeing attendees tomorrow. ➡️ Register here: https://lnkd.in/eMzVzaJB #TBresearch #Tuberculosis #TB #earlyphasedrugdevelopment AMR Accelerator, International Union Against Tuberculosis and Lung Disease (The Union), NICE - National Institute for Health and Care Excellence, Innovative Health Initiative (IHI), EFPIA - European Federation of Pharmaceutical Industries and Associations, Bill & Melinda Gates Foundation, University of Dundee, TB Alliance